Navigation Links
Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
Date:9/5/2007

Organization Urges Congress to Increase Federal Funding for Deadly, Incurable Disease

SAN JOSE, Calif., Sept. 5 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is launching an advertising campaign aimed at Members of Congress in support of its National IPF Awareness Week Sept. 22-29, 2007.

The campaign, which includes both print and online ads, will kick off on Sept. 6 and urge Members of Congress to take action to increase research funding for idiopathic pulmonary fibrosis (IPF), and to improve education and awareness of the disease in the medical community and general public. Prevalence of IPF has increased more than 150 percent since 2001. There is no FDA approved treatment and no cure for the disease that will claim 40,000 lives this year.

"The silence around IPF is deafening," said Mark Shreve, chief executive officer of the CPF. "This campaign represents the voices of thousands of patients who are too debilitated to travel to Capitol Hill during IPF Awareness Week and speak for themselves."

The campaign will appear in print in Congressional Quarterly's CQ Today on Sept. 6, 12, 20 and 25, and in Congressional Quarterly's online publication HealthBeat the weeks of Sept. 10 and 24.

"This campaign is a critical component of IPF Awareness Week to advance our efforts to represent the needs of this community of patients and researchers as aggressively as possible," said Shreve. "Our goal is to get the attention of Members of Congress and their staffs to gain their support for increased funding for research, education and awareness while also furthering legislation that impacts IPF patients and their families."

The ad campaign was created pro bono by Jeff Hardy, owner of Floor Eighty-Four Studio in Los Angeles, Calif. Hardy recently lost his grandfather to IPF.

To view the CPF's ads, please visit: http://www.coalitionforpf.org.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 13,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. Long travel increase pulmonary embolism
3. CT Pulmonary Angiography Scan More Effective In Detecting Dangerous Blood Clots In The Legs
4. FDA Approves Remodulin for Pulmonary Hypertension
5. Antipsychotic Drug Linked to Pulmonary Embolism
6. Treating Pulmonary Arterial Hypertension In Children With Viagra
7. Pulmonary rehabilitation program effective for chronic obstructive pulmonary disease
8. People Suffering From Chronic Pulmonary Disease To Get Relief From Harmonica
9. Risk Factors Can Identify Pulmonary Embolism
10. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
11. Malfunction Of Key Growth Factor Increases Mortality Rate From Pulmonary Fibrosis In Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: